Onconic Therapeutics Inc. (KOSDAQ:476060)
South Korea flag South Korea · Delayed Price · Currency is KRW
21,250
-650 (-2.97%)
Apr 30, 2026, 3:30 PM KST

Onconic Therapeutics Ratios and Metrics

Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year
CurrentFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Apr '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
953,867869,777176,537---
Market Cap Growth
257.78%392.69%----
Enterprise Value
901,257816,363152,373---
Last Close Price
21250.0019550.004085.00---
PE Ratio
60.4355.11----
PS Ratio
17.8716.2911.90---
PB Ratio
13.2412.073.15---
P/TBV Ratio
13.2412.073.15---
P/FCF Ratio
85.9978.41----
P/OCF Ratio
83.7176.33----
EV/Sales Ratio
16.8815.2910.27---
EV/EBITDA Ratio
68.5562.09----
EV/EBIT Ratio
71.4264.69----
EV/FCF Ratio
81.2573.60----
Debt / Equity Ratio
0.000.000.01-0.720.00-0.02
Debt / EBITDA Ratio
0.010.01-5.26--
Debt / FCF Ratio
0.010.01-4.74--
Net Debt / Equity Ratio
-0.73-0.73-0.760.811.242.34
Net Debt / EBITDA Ratio
-4.00-4.009.82-6.281.852.25
Net Debt / FCF Ratio
-4.74-4.745.35-5.341.562.11
Asset Turnover
0.780.780.300.620.00-
Quick Ratio
17.4817.4810.610.541.0636.08
Current Ratio
17.6217.6210.940.541.0636.10
Return on Equity (ROE)
24.65%24.65%-44.55%---
Return on Assets (ROA)
11.55%11.55%-6.09%4.07%-36.85%-
Return on Capital Employed (ROCE)
17.50%17.50%-8.50%-11.50%-343.70%-44.10%
Earnings Yield
1.65%1.81%-4.58%---
FCF Yield
1.16%1.27%-4.52%---
Buyback Yield / Dilution
---41.46%0.00%-0.94%-
Source: S&P Global Market Intelligence. Standard template. Financial Sources.